Difference between revisions of "Invasive ductal carcinoma of the pancreas"

Jump to navigation Jump to search
prognosticator
(prognosticator)
 
(11 intermediate revisions by 2 users not shown)
Line 11: Line 11:
| IHC        =
| IHC        =
| EM        =
| EM        =
| Molecular  = +/-BRCA2 carrier
| Molecular  = +/-[[BRCA2]] carrier
| IF        =
| IF        =
| Gross      =
| Gross      =
Line 22: Line 22:
| Symptoms  =
| Symptoms  =
| Prevalence = common for site
| Prevalence = common for site
| Bloodwork  =
| Bloodwork  = elevated CA19-9
| Rads      = pancreatic mass
| Rads      = pancreatic mass
| Endoscopy  =
| Endoscopy  =
Line 30: Line 30:
| Tx        = surgery if possible
| Tx        = surgery if possible
}}
}}
'''Invasive ductal carcinoma of the pancreas''' is the most common type of [[pancreas|pancreatic]] [[cancer]].
'''Invasive ductal carcinoma of the pancreas''' is the most common type of [[pancreatic cancer]].


It is typically gland forming and thus also referred to as '''pancreatic ductal adenocarcinoma''' and '''pancreatic adenocarcinoma'''.
It is typically gland forming and thus also referred to as '''pancreatic ductal adenocarcinoma''' and '''pancreatic adenocarcinoma'''.
Line 39: Line 39:
*Location: usually in the head ~60%.
*Location: usually in the head ~60%.
**15% in the body, 5% tail, 20% diffuse (head, body & tail).<ref name=Ref_PBoD950>{{Ref PBoD|950}}</ref>
**15% in the body, 5% tail, 20% diffuse (head, body & tail).<ref name=Ref_PBoD950>{{Ref PBoD|950}}</ref>
**The vast majority of pancreatic cancers are solitary, but multifocal disease can occur.
*Abysmal prognosis.
*Abysmal prognosis.


Line 44: Line 45:
*Smoking (RR ~ 2).
*Smoking (RR ~ 2).
*Pancreatitis.
*Pancreatitis.
*Family history, esp. BRCA2.
*Family history, esp. [[BRCA2]].
*[[Diabetes mellitus]] - modest risk increase.
*[[Diabetes mellitus]] - modest risk increase (RR ~ 1.5-2).
*Previous gastrectomy.
*Heavy drinking of alcohol may weakly increase risk.  


Molecular characteristics:<ref name=Ref_PCPBoD8_470-1>{{Ref PCPBoD8|470-1}}</ref><ref name=pmid19896096>{{Cite journal  | last1 = Furukawa | first1 = T. | title = Molecular pathology of pancreatic cancer: implications for molecular targeting therapy. | journal = Clin Gastroenterol Hepatol | volume = 7 | issue = 11 Suppl | pages = S35-9 | month = Nov | year = 2009 | doi = 10.1016/j.cgh.2009.07.035 | PMID = 19896096 }}</ref>
Molecular characteristics:<ref name=Ref_PCPBoD8_470-1>{{Ref PCPBoD8|470-1}}</ref><ref name=pmid19896096>{{Cite journal  | last1 = Furukawa | first1 = T. | title = Molecular pathology of pancreatic cancer: implications for molecular targeting therapy. | journal = Clin Gastroenterol Hepatol | volume = 7 | issue = 11 Suppl | pages = S35-9 | month = Nov | year = 2009 | doi = 10.1016/j.cgh.2009.07.035 | PMID = 19896096 }}</ref>
Line 52: Line 55:
#TP53 (AKA p53).
#TP53 (AKA p53).
#SMAD4.
#SMAD4.
Clinical:
*Serum CA19-9 - >2504 U/ml predicts outcome.<ref name=pmid28924968>{{Cite journal  | last1 = Usón Junior | first1 = PLS. | last2 = Callegaro-Filho | first2 = D. | last3 = Bugano | first3 = DDG. | last4 = Moura | first4 = F. | last5 = Maluf | first5 = FC. | title = Predictive Value of Serum Carbohydrate Antigen 19-9 (CA19-9) for Early Mortality in Advanced Pancreatic Cancer. | journal = J Gastrointest Cancer | volume = 49 | issue = 4 | pages = 481-486 | month = Dec | year = 2018 | doi = 10.1007/s12029-017-0007-x | PMID = 28924968 }}</ref>
==Gross==
Features:<ref name="pmid2015921">{{Cite journal  | last1 = Hermanek | first1 = P. | title = Staging of exocrine pancreatic carcinoma. | journal = Eur J Surg Oncol | volume = 17 | issue = 2 | pages = 167-72 | month = Apr | year = 1991 | doi =  | PMID = 2015921 }}</ref>
*Firm, sclerotic and poorly defined masses that replace the normal lobular architecture of the gland.
*Cut surface are yellow to white.
*The mean diameter of pancreatic head tumor is between 2.5-3.5cm.


==Microscopic==
==Microscopic==
48,830

edits

Navigation menu